FiercePharma: ASH: J&J makes case for Tecvayli combo as an alternative to CAR-T in 2nd-line multiple myeloma
ASH: J&J makes case for Tecvayli combo as an alternative to CAR-T in 2nd-line multiple myeloma
Morningstar: Tec-Dara Combination Offers Substantial Improvement Over Standard Second-Line Therapies for Relapsed or Refractory Multiple Myeloma
To test this hypothesis, researchers randomized 587 patients with R/R multiple myeloma to receive either Tec-Dara or standard second-line therapies. For patients in the control arm, treating ...
Tec-Dara Combination Offers Substantial Improvement Over Standard Second-Line Therapies for Relapsed or Refractory Multiple Myeloma
Sarclisa (isatuximab) has been approved in the US since 2020, initially for relapsed/refractory multiple myeloma before moving into the frontline setting in 2024, and saw sales grow 28% to €588 ...
WebMD: Tecvayli Plus Darzalex Faspro: FDA Approves Under‑the‑Skin Combo Immune Therapy as a New Second-Line Option for Multiple Myeloma
Tecvayli Plus Darzalex Faspro: FDA Approves Under‑the‑Skin Combo Immune Therapy as a New Second-Line Option for Multiple Myeloma
MSN: Tec-Dara combination offers improvement over standard second-line therapies for relapsed, refractory multiple myeloma
Tec-Dara combination offers improvement over standard second-line therapies for relapsed, refractory multiple myeloma
EurekAlert!: Tec-Dara combination offers substantial improvement over standard second-line therapies for relapsed or refractory multiple myeloma
The American Journal of Managed Care: Examining Key Updates in First-Line Treatment Options for Multiple Myeloma
The American Journal of Managed Care: Advancing First-Line Therapy for Multiple Myeloma: Updates From IsKia and IMROZ Trials
Advancing First-Line Therapy for Multiple Myeloma: Updates From IsKia and IMROZ Trials
The American Journal of Managed Care: How Teclistamab Is Rewriting Second-Line Myeloma Care: Roberto Mina, MD